Genprex, Inc. · NASDAQ:GNPX
Genprex — Investor Presentation (March 2021)
46 slides from Genprex's investor presentation, Mar 9, 2021
Slide 1: Reprogramming the Course of Cancer and Diabetes
©) Genprex REPROGRAMMING THE COURSE OF CANCER AND DIABETES NASDAQ: GNPX Updated March 9, 2021
Slide 2: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS ‘Statements contained in this presentation regarding matters that are not historical facts are “forward-lookingstatements" within the meaning of the Private Securities Litigation Reform Actof 1995. Because such statements are subjectto risks and uncertainties, actual resul
Slide 3: GNPX at a Glance
GNPX AT A GLANCE 10-DAY AVG SHARES COMPANY SYMBOL EXCHANGE | SHARE PRICE? | MARKET C) BENS Nagi nceane: Genprex, Inc. GNPX Nasdaq $5.38 $254M 14M. 47,276,764 $56,111,196 1:As of March 1,2021. Bosed on closing price as of March 1, 2021 and pro-forma shares outstanding os of February 11, 2021. 3: Cash
Slide 4: Major Competitive Advantages
MAJOR COMPETITIVE ADVANTAGES GENE THERAPY PLATFORM. Our non-viral Oncoprex® nanoparticle delivery system is designed to deliver a variety of therapeutic genes to fightcancer. Data indicate ‘that our lead drug candidate, REQORSA immunogene therapy, may be combined witha number of approved cancer drug
Slide 5: Executive Summary
EXECUTIVE SUMMARY GENE THERAPY PLATFORM FIRST SYSTEMIC GENE THERAPY USED FOR CANCER IN HUMANS LARGE MARKETS AND UNMET NEED COMBINATION TRIALS WITH TOP SELLING CANCER DRUGS FDA FAST TRACK DESIGNATION MAJOR COMPETITIVE ADVANTAGES, DEMONSTRATED CLINICAL ACHIEVEMENT INITIATING TWO LUNG CANCER TRIALS IN
Slide 6: Fast Track Designation
FAST TRACK DESIGNATION ~ * we Genprex received Fast Track Designation (FTO) for REQORSA + AstraZeneca’s Tagrisso for non-small cell lung cancer (NSCLO) patients that progressed on Tagrisso. Tagrisso had $4B+ worldwide gross sales in 2020, and itis Astrazeneca’s highest grossing product. FTD is for t
Slide 7: Research and Development Pipeline
© Genprex RESEARCH AND DEVELOPMENT PIPELINE CLINICAL, ‘CLINICAL CLINICAL, DISCOVERY PRECLINICAL. es Gree ores ‘ONCOLOGY REQORSA™ + TARGETED THERAPIES Acclaim-1 Ea REQORSA™ + IMMUNOTHERAPIES Acclaim 2 SS > VARIOUS ONCOLOGY TARGETS DIABETES — Ie siesta Nasdaq: GNPX
Slide 8: Acclaim-1 General Study Characteristics
“allt? Acclaim - 1 GENERAL STUDY CHARACTERISTICS + REQORSA in combination with AstraZeneca's Tagrisso for NSCLC + Patients with Stage 4, EGFR mutant NSCLC whose disease progressed after Tagrisso + ~15 US. sites + -92 patients Phase 1: 9-18 patients Phase 2: 74 patients Interim analysis at 51 events
Slide 9: Acclaim-1 Phase 1 and Phase 2 Design
oF wz 2O fa PHASE 2 COMPONENT 343 dose escalation of REQORSA in combination with Tagrisso Randomized 1:1, open-label, 2arm study of REQORSA in combination with Tagrisso vs, Tagrisso monotherapy PRIMARY ENDPOINT + Dose limiting toxicity PRIMARY ENDPOINT + Progression free survival (PFS) + PFS improve
Slide 10: Bridging Gaps in Modern Medicine
BRIDGING GAPS IN MODERN MEDICINE HELPING PATIENTS WITH LIMITED TREATMENT OPTIONS ONCOLOGY DIABETES * Genprex’s oncology combination treatment © Gene therapy drug candidate addresses Type 1 and approach utilizes targeted therapies and Type 2 diabetes. immunotherapies. * May reduce or eliminate daily
Slide 11: Oncology Program
Slide 12: Non-Small Cell Lung Cancer
NON-SMALL CELL LUNG CANCER MARKET STATISTICS A% 4B+ MOST COMMON LUNG CANCER TAGRISSO® 2020 SALES NSCLC represents the majority of all lung cancers. AstraZeneca’s highest grossing product. 14B+ WORLDWIDE CASES KEYTRUDA® 2020 SALES More than two million cases per year worldwide. Merck's highest grossi
Slide 13: Novel Platform to Treat Cancer
NOVEL PLATFORM TO TREAT CANCER ONCOPREX® NANOPARTICLE DELIVERY SYSTEM GENES Multiple tumor suppressor genes SYNERGIES Modern approach using combination therapy CANCERS Genetic mutations found in other cancers Genprex NasdagscNex >
Slide 14: Oncoprex Nanoparticle Delivery System
ONCOPREX NANOPARTICLE DELIVERY SYSTEM CATIONIC LIPID NANOPARTICLE CARRIES DRUG TO TUMORS Positively charged TUSC2 gene nanoparticle | Cassette S) (S) om > —_— — le (S) Nanoparticle attaches Cancer killing genes Cell death to cancer cell integrate into cell Negatively charged cancer cell Our non-vira
Slide 15: Targeting Negative Surface Charges of Cancer Cells
TARGETING NEGATIVE SURFACE CHARGES OF CANCER CELLS AN IDEAL MEANS TO SELECTIVELY TARGET CANCER CELLS + The activities of glucose metabolism have a profound impact on the surface of cancer cells, + Elevated glycolysis in cancer cells lead to a higher secretion of lactate Secreted lactate ions remove
Slide 16: REQORSA Targets Cancer at Its Core
REQORSA™ TARGETS CANCER AT ITS CORE DOTAP: CHOL-TUSC2 —a z a8 mS oe CONTROLS CELL SIGNALING STIMULATES APOPTOTIC PATHWAYS = MODULATES IMMUNE RESPONSE Pan-kinase inhibition decreases cell Leads to programmed cell death Promotes immune activity against proliferation cancer Genpre Nasdaq: GNPX
Slide 17: TUSC2 Inhibits Key Cell Signaling
TUSC2 INHIBITS KEY CELL SIGNALING TUSC2 TUMOR SUPPRESSOR GENE HAS PAN-KINASE ACTIVITY THAT CAN OVERCOME CANCER RESISTANCE PATHWAYS Nasdaq: GNPX
Slide 18: REQORSA Modulates the Immune System
REQORSA MODULATES THE IMMUNE SYSTEM = CcrvorPembrorrusc2 A Active T cells (Lung) Pon In Lung Metastasis. NK in Lung Metastasis = 19- 20 Fy ¥ 2 E;, Sm. ae 3 : g Gao Be 3s. i = Er Immunomodulation of Carbo + Pembro + °. . £ TUSC2 demonstrates rationale for the pater irs as Pi Acclaim-1 and Acclaim-2 c
Slide 19: REQORSA Monotherapy
REQORSA MONOTHERAPY ONC-001 TRIAL DOSE ESCALATION STUDY Explore toxicity and tolerability in patients. Phase 1 monotherapy results: 31 Stage IV patients with at least 1 of 6 trial doses 23 patients evaluable Cancer growth halted in 5 of 23 patients Stable disease n=5; responses n=3 Maximum Tolerated
Slide 20: REQORSA + Tarceva Combination
REQORSA + TARCEVA COMBINATION PHASE 2 PRELIMINARY DATA IN SUBJECTS WITH OR WITHOUT EGFR MUTATIONS PATIENT EGFR STATUS RESPONSE PRIOR THERAPY eee Positive (exon 18420) Complete Response chemo Negative 24% regression Target Lesion Chemo /anti-PD1 a 30% regression one Target Lesion Negative 18% regress
Slide 21: REQORSA + Tarceva Combination Best Response
EGFR status/mutation REQORSA + TARCEVA COMBINATION s\ mer Plot of Best Response, with Time on Study Negative 4 Negative 4 Positive (exon 18+20) 4 Negative 4 Negative 4 Negative 4 Negative 4 Negative 4 sD Positive (exon 21) 4 a@uadiccey Neestie'-7 aa 4 Chemotherapy+Immunotherapy Negative 4 sD Bae Pos
Slide 22: REQORSA Shows Synergy with Immunotherapies
REQORSA SHOWS SYNERGY WITH IMMUNOTHERAPIES REQORSA IS SYNERGISTIC WITH ANTI-PD1 IN A SYNGENEIC MOUSE MODEL OF LUNG CANCER ‘Survival on Lung Metastasis Model Non-treated TUsce-treated 100 me powers is = = Tusce 2 == tusc2-o+ i a == tuscarrorscttas & od 10 6 Ey zs Days TUSC2+anti-PD1 exhibit greater a
Slide 23: REQORSA Synergistic with Anti-PD1 in Humanized Mouse Model
Strong antitumor immune responses of anti-PD1 were REQORSA SHOWS SYNERGY WITH IMMUNOTHERAPIES REQORSA IS SYNERGISTIC WITH ANTI-PD1IN A HUMANIZED MOUSE MODEL OF LUNG CANCER REQORSA + Keytruda found against PDX tumors developed in humanized mice. see Sao Poms seam, REQORSA + Keytruda + Chemo REQORSAta
Slide 24: nS ae wi ov <2 Oa
nS ae wi ov <2 Oa
Slide 25: Diabetic Patients in Need of Modern Therapy
DIABETIC PATIENTS IN NEED OF MODERN THERAPY GPX-002 MAY ELIMINATE NEED FOR INSULIN IN DIABETIC PATIENTS Type 1 and Type 2 diabetes affect approximately 34 million people in the U.S', or 10 percent of the U.S. population. May replace daily burden of blood glucose monitoring and insulin replacement th
Slide 26: GPX-002 Replenishes Levels of Insulin
GPX-002 REPLENISHES LEVELS OF INSULIN REPROGRAMS AND RESTORES CELL FUNCTION Novel infusion process uses an endoscope and an AAV vector to deliver the Pdx1 and MafAgenes to the pancreas. Transforms alpha cells in the pancreas into functional beta-like cells, which can produce insulin but are distinct
Slide 27: Key Milestones Through 2021 & Beyond
KEY MILESTONES THROUGH 2021 & BEYOND Receive anticipated U.S. Food and Drug Administration (FDA) ‘clearance for the Acclaim clinica trials Dose the first patient in each of the Acclaim clinical trials. Announce interim data from the Acclaim clinical trials Report preclinical data related to our Spon
Slide 28: Some Targeted Therapy Company Valuations
SOME TARGETED THERAPY COMPANY VALUATIONS , ; DRUG COMPANY SYMBOL EXCHANGE INDICATION aesy| GIGS VALUATION noe Melanoma, Head and Neck, ereakNSEtC Chrone UfleuelLN-4S—Phase3ti2) S87 Bon ee fig Selec Wirge'Theapeutis MTX nasdag — NSCLE,COINECELRENA! rye server Prase32) 102 Bon ape Eninosta Arai, i nas
Slide 29: Meet Our Team
MEET OUR TEAM COMPANY MANAGEMENT RODNEY VARNER, JD CATHERINE VACZY Chairman, President & Chief Executive Officer Executive VP, General Counsel & Chief Strategy Officer + 20+ years of expertisein corporate law, including corporate governance, in biotech industry + 20+ years of experiencein senior exe
Slide 30: Meet Our Team
MEET OUR TEAM COMPANY MANAGEMENT THOMAS GALLAGHER, JD Senior Vice President, Intellectual Property and Licensing + 20+ years of expertise in biotech IP law, business development, licensing transactions + Seasoned IP executive and attorney SHANNON INMAN Vice President of Global Clinical Operations +
Slide 31: Scientific Advisory Board
MEET OUR TEAM SCIENTIFIC ADVISORY BOARD PASI ANTERO JANNE MD, PhD + Professor of Medicine, Harvard Medical School: Director of Dana Farber Cancerlnstitute Lowe Center for Thoracic Oncology; Scientific Director of the Belfer Centerfor Applied Cancer Science JACK A. ROTH MD, FACS, Chairman Professor a
Slide 32: Clinical Advisory Board
MEET OUR TEAM CLINICAL ADVISORY BOARD MICHAEL MORSE MD, MHS, FACP + Professor of Medicine, Division of Medical Oncology in the Department of Surgery at Duke University + Research expertise in targeted therapies and immunotherapies for cancer ANDREW BECKER MD, PHD + President and Founder, Becker Phar
Slide 33: Board of Directors
Coming Soon MEET OUR TEAM BOARD OF DIRECTORS RODNEY VARNER, JD Chairman of the Board MN BRENT LONGNECKER Board Director + 30+ years of expertise in corporate law, including corporate governance, in biotech industry + Former owner of securities broker dealer firm +: Chief ene ornten!leneriee tens eer
Slide 34: 21st Century Gene Therapies
21ST CENTURY GENE THERAPIES LARGE MARKETS AND UNMET NEED IN A FUTURE OF COMBINATION TRIALS WITH TOP TRANSFORMATIONAL SELLING DRUGS FAST TRACK DESIGNATION PATIENT CARE EXPLORING NEW INDICATIONS AND PARTNERSHIPS Nasdaq: GNPX
Slide 35: Genprex Contact
oO Genprex’ NASDAQ: GNPX 1601 Trinity St, Bldg B, #3.312.09, Austin, Texas 78712 (877)774-GNPX | investors@genprex.com Nasdaq: GNPX
Slide 36: Appendix
Slide 37: Preparing to Initiate Two New Combination Clinical Trials
PREPARING TO INITIATE TWO NEW COMBINATION CLINICAL TRIALS FIRST-HALF OF 2021 =" KEYTRUDA i. a tl (pembrolizumab) v-vis:snsam | (ONCOPREX® Nanoparticle Delivery System isthe lipid nanoparticle delivery system used in REQORSA™. Nasdaq: GNPX
Slide 38: Effects of Genetic Alterations in Suppressor Genes
EFFECTS OF GENETIC ALTERATIONS IN SUPPRESSOR GENES The most common genetic alterations present in NSCLC are located in tumor-suppressor genes against whichno targeted agents have been developed. Regulation of Malignant Tumor Growth = Insensitivity to Growth-inhibitory Signals = Evasions of Programme
Slide 39: Why Systemic Gene Therapy?
WHY SYSTEMIC GENE THERAPY? Lipid nanoparticles have been shown to encapsulate plasmid DNA, which allows the delivery of gene therapeutic agents intravenously to distant metastases Lipid nanoparticles with TUSC2 have up to a 33-fold affinity for cancer cells compared to healthy cells No need to attac
Slide 40: Why TUSC2?
WHY TUSC2? = 80% ofall lung cancer cells lack the TUSC2 tumor suppressor gene » Loss or reduction of TUSC2 expression is associated with significantly worse overall survival + Premalignantlesions express significantly lower levels of TUSC2 compared with normal bronchial epithelia © Genprex Nasdag:GN
Slide 41: Viral vs. Non-Viral Vectors
VIRAL VS. NON-VIRAL VECTORS The most common viral vectors are adenoviruses and retroviruses = High level of transfection efficiency + Generally stable = Less specificity of target cells = Can be immunogenic because capsid and viral proteins cause inflammation = Reported cases of death and causing le
Slide 42: Other Potential Cancer Indications
OTHER POTENTIAL CANCER INDICATIONS The region of the TUSC2 tumor suppressor gene is associated with chromosome 3p. In addition to NSCLC, other potential indications include: + Thyroid + Renal «= Breast + Head &Neck + Mesothelioma + Ovary Ivanova, AV, Ivanov, 5.V, Prudkin, Let ol. Mechanisms of FUS 1
Slide 43: REQORSA + Tagrisso Reduce Tumor Growth
REQORSA + TAGRISSO REDUCE TUMOR GROWTH 2a i i Se ed ee ree t t Osimertinib+TUSC2 combination on é Osimertinib+TUSC2 combination on HiSTe emt tumors tn Neo mace H1975 tumors in NSG mice 200 * Ea. E iso — 5 & 3 10 2 5 $ 200. eee on 12 —— | °. °. Det 025 029 O32 036 059 43 21 25 p29 52 D6 050 Days Days
Slide 44: REQORSA + Tagrisso Reduce Tumor Growth
REQORSA + TAGRISSO REDUCE TUMOR GROWTH (Osimertinib+TUSC2 on AS49 lung met in NSG mice Week 3 N= 10meceoroup Tumor ntnsity (toa fx [p) ry & & f & * p=0.001 vseont +p =0.005 vs Osimertind Figure 4A. TUSC2 combination with Osimertinib inhibits tumor growth and significantly prolongs survival. A) top;
Slide 45: Effect of REQORSA + Carbo + Keytruda on Humanized A549 Lung Metastasis Model
EFFECT OF REQORSA + CARBO + KEYTRUDA ON HUMANIZED A549 LUNG METASTASIS MODEL Carbo+Pembro Effect of Carbo+Pembro+TUSC2 on Tusc2 Carbo+Pembro_+TUSC2 A549 lung met on Hu-NSG g 60000 ——— = Sz gz o= S- Se $a s x ) Genprex Pembrolzumab isthe generic form of Keytruda, asda GNPx
Slide 46: Effect of REQORSA + Carbo + Keytruda on Humanized A549 Lung Metastasis Model
EFFECT OF REQORSA + CARBO + KEYTRUDA ON HUMANIZED A549 LUNG METASTASIS MODEL Effect of CarbotPembro+TUSC2 on A549 lung met on Hu-NSG. 6%10°4-~ No treatment -—® TUSC2 4x10° .- Carbo+Pembro £ 2 g —* Carbo+Pembro+TUSC2 & axtoe. 3 A % 2x108 $1.5%10°. F 4x108. tee 5x 107, ea 0 T T T p14 28 D35 "* p= 0.00